Intra-Cellular Therapies (ITCI) Financials

Intra-Cellular Therapies Inc (ITCI) is a biopharmaceutical company focused on the development and commercialization of innovative treatments for neurologic and psychiatric disorders. The company's income statement provides a snapshot of its financial performance over a specific period of time. It shows the revenue generated from the sale of its products and services, as well as the expenses incurred in producing and delivering those products. Intra-Cellular Therapies Inc (ITCI) reported a total revenue of $41.1 million for the latest fiscal year, with a gross profit of $27.6 million. The company's net income from stockholders was $-188.9 million, indicating a loss for the year.

To assess the company's profitability before interest and taxes, investors can look at the earnings before interest and taxes (EBIT) figure. Intra-Cellular Therapies Inc (ITCI) reported an EBIT of $-204.1 million for the latest fiscal year, which reflects its operating performance without consideration for interest expenses and taxes. Another profitability measure, earnings before interest, taxes, depreciation, and amortization (EBITDA), was also negative at $-183.2 million for the same period. EBITDA provides a clearer view of a company's underlying operating performance by excluding non-cash expenses like depreciation and amortization.

In terms of its financial position, Intra-Cellular Therapies Inc (ITCI) had total assets of $591.8 million and total liabilities of $209.1 million as of the latest reporting period. The company's stockholders' equity, which represents the net worth of the business, was recorded at $382.7 million. The balance sheet also indicates the amount of debt the company has taken on, referred to as total debt, which stood at $109.6 million. The company's net debt, calculated by subtracting cash equivalents from total debt, amounted to $104.3 million.

Intra-Cellular Therapies Inc (ITCI) also provides information on its cash flow, which can indicate the company's financial health and its ability to generate cash. The cash flow statement categorizes the company's cash inflows and outflows into three main areas: operating activities, investing activities, and financing activities. For Intra-Cellular Therapies Inc (ITCI), the operating cash flow was -$197.4 million for the latest fiscal year, while the investing cash flow was -$1.8 million. The financing cash flow, which includes activities such as issuing or repurchasing stock and paying dividends, was -$1.2 million. The company's free cash flow, which represents the amount of cash generated from its core operations minus capital expenditures, was -$47.6 million.

Overall, Intra-Cellular Therapies Inc (ITCI) faces significant financial challenges as it continues to invest in the development of its pipeline and commercialization efforts. The company has been reporting net losses in recent years, indicating the high costs associated with research and development in the biopharmaceutical industry. However, with its strong total assets and stockholders' equity, Intra-Cellular Therapies Inc (ITCI) is well-positioned to continue its mission of developing innovative treatments for neurologic and psychiatric disorders.